The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
你是否在夜间常常感到呼吸困难,或是听到身边的人打鼾声不断?这可能是阻塞性睡眠呼吸暂停(OSA)的表现,而最新的消息显示,FDA已批准礼来公司的减肥药物Zepbound用于治疗这种常见但被广泛误解的睡眠障碍。这一突破性的进展,将对数以亿计的患者产生深远的影响。 阻塞性睡眠呼吸暂停的患者在睡梦中可能会因呼吸道受到阻塞而短暂停止呼吸,这不仅影响睡眠质量,还可能引发心脏病等其他严重健康问题。根据研究,全球 ...
FDA批准Zepbound用于“治疗肥胖成人的中度至重度阻塞性睡眠呼吸暂停”。此前的治疗方法主要包括持续正压通气 (CPAP)机器,它通过面罩持续输送气流以保持呼吸道通畅。手术也是一种选择。
The drug was launched in the U.S. back in 2023 to treat obesity.
礼来 (LLY.US)盘前涨2.12%报784美元。消息上,当地时间周五 (12月20日),美国食品和药品管理局 (FDA)批准 礼来公司的减肥药物Zepbound用于治疗阻塞性睡眠呼吸暂停 (OSA),使其成为首个获批直接治疗这一常见 睡眠障碍 ...
Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...
近年来,减肥药物市场一度成为投资者关注的焦点,随着Novo Nordisk的Wegovy和Eli ...
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
The Broadway icon said he’s a “great believer” in the weight-loss medication, which helped him after he weighed 310 lbs.
当地时间周五(12月20日),美国食品和药品管理局(FDA)批准礼来公司的减肥药物Zepbound用于治疗阻塞性睡眠呼吸暂停(OSA),使其成为首个获批 ...